Athyrium Capital Management LP and Neuberger Berman has closed its latest healthcare fund at about $2.025 billion. The limited partners of Athyrium Opportunities Fund III include public and private ...

Investment company Athyrium Capital Management, LP (Current Portfolio) buys Recro Pharma Inc during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Athyrium ...

Athyrium Opportunities Fund LP, a private credit fund which invests in healthcare sector, has closed at $507 million. The Fund, which was oversubscribed, is jointly managed by Neuberger Berman and ...

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and ...

Fintel reports that Athyrium Opportunities 2020 LP has filed a 13D/A form with the SEC disclosing ownership of 71,136,069 shares of Biora Therapeutics Inc (BIOR). This represents 28.4% of the company.

NEW YORK--(BUSINESS WIRE)--A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. today announced they have exited their ...

Athyrium Capital Management has raised a $1.2 billion healthcare fund, cash earmarked for investments in commercial-stage healthcare companies. Working with investment manager Neuberger Berman, the ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has entered into a note purchase agreement with a fund of Athyrium Capital ...

(RTTNews) - Basilea Pharmaceutica Ltd said it will accelerate the repayment of senior secured loan. The senior secured loan from Athyrium Capital Management, LP had an initial total amount of 75 ...

OptiNose Inc., a drug company that went public last year after receiving backing from Avista Capital Partners, agreed to a $100 million debt financing with health care-focused investor Athyrium ...